<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04724590</url>
  </required_header>
  <id_info>
    <org_study_id>83045809-604.01.02</org_study_id>
    <secondary_id>159075</secondary_id>
    <nct_id>NCT04724590</nct_id>
  </id_info>
  <brief_title>OPHTHALMOLOGIC EVALUATION OF RADIATION-RELATED OPTIC NEUROPATHY FOLLOWING IMAGE GUIDED INTENSITY-MODULATED RADIATION THERAPY (IMRT) FOR NASOPHARYNGEAL CARCİNOMA</brief_title>
  <acronym>ORONIN</acronym>
  <official_title>OPHTHALMOLOGIC EVALUATION OF RADIATION-RELATED OPTIC NEUROPATHY FOLLOWING IMAGE GUIDED INTENSITY-MODULATED RADIATION THERAPY (IMRT) FOR NASOPHARYNGEAL CARCİNOMA (ORONIN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istanbul University-Cerrahpasa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istanbul University-Cerrahpasa</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary treatment in nasopharynx cancers is radiotherapy (RT) or chemoradiotherapy (CRT)&#xD;
      depending on the stage of the tumor. According to the guidelines, the dose of radiotherapy&#xD;
      for primary tumors varies between 66-70 Gy. In consideration of modern radiotherapy&#xD;
      techniques like IMRT with systemic chemotherapy for nasopharyngeal cancer, loco-regional&#xD;
      control has been perfect. However, the rate of late complications from treatment, many of&#xD;
      which are irreversible, is still high. Radiation-related optic neuropathy is the late&#xD;
      complication that optic nerves might be affected during the radiotherapy due to the close&#xD;
      location of the nasopharynx. Incidence of this is 8.7-9% in head and neck cancer and is&#xD;
      observed between 2-9 years after RT. Painless, irreversible, and progressive vision loss&#xD;
      usually occurs, and the pallor of optic disc margins, retinal vein dilatation, bleeding, and&#xD;
      neovascularization are in the ophthalmic examination. The risk of optic neuropathy increases&#xD;
      when the tumor is in close contact with optic nerves, radiation dose, concurrent chemotherapy&#xD;
      used, history of diabetes or hypertension.&#xD;
&#xD;
      The aim of our study is to prospectively evaluate optic neuropathy in nasopharynx cancer&#xD;
      patients treated in our clinic.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 3, 2020</start_date>
  <completion_date type="Anticipated">May 3, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 3, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Prospective study</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>OPHTHALMOLOGIC EVALUATION OF RADIATION-RELATED OPTIC NEUROPATHY FOLLOWING IMAGE GUIDED INTENSITY-MODULATED RADIATION THERAPY (IMRT) FOR NASOPHARYNGEAL CARCİNOMA (ORONIN) RADIATION-RELATED OPTIC NEUROPATHY</measure>
    <time_frame>2-9 years</time_frame>
    <description>RADIATION-RELATED OPTIC NEUROPATHY</description>
  </primary_outcome>
  <enrollment type="Anticipated">15</enrollment>
  <condition>The Aim of Our Study is to Prospectively Evaluate the Optic Neuropathy in Nasopharynx Cancer Patients</condition>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>IMRT(IMAGE GUIDED INTENSITY-MODULATED RADIATION THERAPY )</intervention_name>
    <description>Evaluation the optic neuropathy in nasopharynx cancer patients treated in our clinic.</description>
    <other_name>OCT(Optical Coherence Tomography), OCT-A(Optical Coherence Tomography Angiography)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patient with nasopharyngeal carcinoma that histopathologically confirmed Age &gt;18&#xD;
        Radiotherapy or chemoradiotherapy applied to the patient in our clinic No recurrence or&#xD;
        metastasis during follow-up Optic evaluation Evaluation with MRI or CT during follow-up&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Cranial RT No histopathological verification Age&lt; 18 There were locoregional recurrence or&#xD;
        metastasis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Meltem Dağdelen, MD</last_name>
    <phone>+905426603810</phone>
    <email>meltemdagdelen@windowslive.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ceren Barlas, MD</last_name>
    <phone>+905052757730</phone>
    <email>dr.cicibiyik@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Meltem Dağdelen</name>
      <address>
        <city>Istanbul</city>
        <zip>34096</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meltem Dağdelen, MD</last_name>
      <phone>+905426603810</phone>
      <email>meltemdagdelen@windowslive.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 21, 2021</study_first_submitted>
  <study_first_submitted_qc>January 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 26, 2021</study_first_posted>
  <last_update_submitted>January 21, 2021</last_update_submitted>
  <last_update_submitted_qc>January 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Istanbul University-Cerrahpasa</investigator_affiliation>
    <investigator_full_name>Meltem Dağdelen</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>RADIATION-RELATED OPTIC NEUROPATHY,NASOPHARYNGEAL CARCİNOMA, RADIOTHERAPY</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
    <mesh_term>Optic Nerve Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

